In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2011

Executive Summary

Biopharma companies raised $3.6 billion in Q1, with almost two-thirds coming from debt sales or follow-on public offerings. Seven of the 19 finalized mergers topped $500 million, but the biggest news was Valeant's attempt to takeover Cephalon. Lilly and BI signed the biggest deal of the quarter when they pooled their diabetes assets in an alliance worth $2.4 billion.
Advertisement

Related Content

Will A Dividend Keep Investors Happy As Amgen Waits For Its Pipeline To Pan Out?
Amgen At A Crossroads: Analysts Question Capital Allocation, M&A,D-mab
Valeant's Bid For Cephalon: Will Opportunism Trump Innovation?
Astellas' Out-Licensing Deal With Cardeus Could Be Model For Development Outsourcing Of More Of Its Portfolio
Valeant CEO Outlines Takeover Rationale, As Cephalon Stays Mum
P&G/Teva Joint Venture Lays Foundation For Switches, Product Launches
Switzerland's Anergis Closes Series A Funding For Allergy Vaccine Trial
Back To School: Big Pharmas Test New Models For Tapping Academia
Back To School: Big Pharmas Test New Models For Tapping Academia
In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel